- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06793397
Una sperimentazione di fase 3 per valutare CYB003 nel disturbo depressivo maggiore (EMBRACE)
Un'efficacia e una sicurezza, fase III, studio multicentrico, in doppio cieco, randomizzato controllato che confronta 2 dosi attive di cyb003 e placebo nei partecipanti ammissibili con disturbo depressivo maggiore
The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD.
For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Clinical Development
- Numero di telefono: 877-361-4003
- Email: clinicaltrialsinfo@cybin.com
Luoghi di studio
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Reclutamento
- Royal Prince Alfred Hospital
-
Investigatore principale:
- Nicholas Glozier
-
-
Queensland
-
Maroochydore, Queensland, Australia, 4558
- Reclutamento
- Thompson Brain & Mind Healthcare (TBMH)
-
Investigatore principale:
- Adem Can
-
Contatto:
- Megan Dutton
- Numero di telefono: +61 4160 40977
- Email: mdutton@tbmh.org.au
-
Contatto:
- Kristy Smyth
- Numero di telefono: +61 4324 41227
- Email: ksmyth@tbmh.org.au
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Reclutamento
- Ramsay Clinic
-
Investigatore principale:
- Malcolm Hopwood
-
Contatto:
- Melanie Hurley
- Numero di telefono: 03 9279 3569
- Email: research.arc@ramsayhealth.com.au
-
Contatto:
- Grace Monigatti
- Numero di telefono: 03 9279 3569
- Email: research.arc@ramsayhealth.com.au
-
Melbourne, Victoria, Australia, 3053
- Reclutamento
- Neurocentrix Research
-
Investigatore principale:
- David Barton
-
Contatto:
- Mai-Anh Bui
- Numero di telefono: +61 3 9546 0009
- Email: mai@neurocentrix.com.au
-
Contatto:
- Gabriela Gonzalez
- Numero di telefono: +61 3 9959 8375
- Email: gabriela@neurocentrix.com.au
-
Notting Hill, Victoria, Australia, 3168
- Reclutamento
- Monash University - Notting Hill
-
Contatto:
- Olivia Lavalette
- Numero di telefono: 0426359494
- Email: olivia.lavalette@monash.edu
-
Investigatore principale:
- Paul Liknaitzky
-
-
-
-
-
Prague, Cechia
- Non ancora reclutamento
- Institute of neuropsychiatric Care (INEP)
-
Investigatore principale:
- Alexander Nawka
-
Contatto:
- Numero di telefono: +420 222 201 020
- Email: info@inep.cz
-
Prague, Cechia
- Non ancora reclutamento
- Psyon s.r.o.
-
Investigatore principale:
- Tomas Palenicek
-
Contatto:
- Numero di telefono: +420 774 401 161
- Email: info@psyon.cz
-
Předměstí, Cechia
- Non ancora reclutamento
- A-SHINE s.r.o.
-
Investigatore principale:
- Lubos Janu
-
Contatto:
- Blanka Vopelková
- Numero di telefono: +490 777 732 244
- Email: blanka.vopelkova@seznam.cz
-
-
-
-
-
Berlin, Germania, 10117
- Non ancora reclutamento
- Charité Universitaetsmedizin Berlin
-
Investigatore principale:
- Michael Koslowski
-
Contatto:
- Numero di telefono: +49 30 450 617734
- Email: psychedelika-studien@charite.de
-
Frankfurt am Main, Germania, 60528
- Non ancora reclutamento
- University Hospital Frankfurt
-
Investigatore principale:
- Andreas Reif
-
Contatto:
- Tanja Scharf
- Numero di telefono: +49 69 6301 86078
- Email: tanja.scharf@unimedizin-ffm.de
-
Mannheim, Germania, 68159
- Non ancora reclutamento
- Central Institute of Mental Health
-
Contatto:
- Karin Bopp
- Numero di telefono: 3016 +49 621 1703 3163
- Email: Karin.bopp@zi-mannheim.de
-
Investigatore principale:
- Gerhard Grüender
-
-
Saarland
-
Homburg, Saarland, Germania, 66421
- Non ancora reclutamento
- Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
-
Investigatore principale:
- Matthias Riemenschneider
-
Contatto:
- Christine Geiger
- Numero di telefono: +49 6841 1624227
- Email: christine.geiger@uks.eu
-
Contatto:
- Aline Freer
- Numero di telefono: +49 6841 1614219
- Email: aline.freer@uks.eu
-
-
-
-
-
Athens, Grecia, 12462
- Reclutamento
- Attikon University Hospital
-
Investigatore principale:
- Nikolaos Smyrnis
-
Contatto:
- Thomas Karantinos
- Numero di telefono: +30697466610
- Email: tkarantinos@gmail.com
-
Athens, Grecia, 11528
- Reclutamento
- Eginitio Hospital
-
Investigatore principale:
- Nikos Stefanis
-
Contatto:
- Adam Adamopoulos
- Numero di telefono: +30 6976032181
- Email: adam_adamopoulos@yahoo.com
-
Thessaloniki, Grecia, 56404
- Reclutamento
- Papageorgiou General Hospital
-
Investigatore principale:
- Georgios Papazisis
-
Contatto:
- Ogla Vampertzi
- Numero di telefono: +306973852659
- Email: olgatrieste@hotmail.com
-
-
-
-
-
Dublin, Irlanda, D24 WK80
- Reclutamento
- Sheaf House - Tallaght Adult Mental Health Service
-
Investigatore principale:
- John Kelly
-
Contatto:
- Ann Connolly
- Numero di telefono: +353 8616 79619
- Email: aconnolly@crp.healthcare
-
Galway, Irlanda, H91 VE03
- Reclutamento
- La Nua Day Hospital Mental Health Centre
-
Contatto:
- Prathyusha Nedunuru
- Numero di telefono: +353 874283750
- Email: pnedunuru@crp.healthcare
-
Investigatore principale:
- Shane McInerney
-
-
-
-
-
Bialystok, Polonia, 15-272
- Ritirato
- Uniwersytecki Szpital Kliniczny W Białymstoku
-
Bydgoszcz, Polonia, 85-133
- Reclutamento
- Promente - Centrum Neurologii i Psychogeriatrii w Bydgoszczy
-
Contatto:
- Franciszek Lauchut
- Numero di telefono: +48 790 219 501
- Email: f.lachut@pro-mente.pl
-
Investigatore principale:
- Katarzyna Lachut
-
Gdansk, Polonia, 80-546
- Reclutamento
- Centrum Badan Klinicznych PI-House Sp. z o.o
-
Contatto:
- Monika Drzewiecka
- Numero di telefono: +48 508-348-938
- Email: m.drzewiecka@pihouse.pl
-
Investigatore principale:
- Hanna Badzio-Jagiello
-
Gdansk, Polonia, 80-214
- Non ancora reclutamento
- UCK
-
Investigatore principale:
- Wieslaw Jerzy Cubala
-
Contatto:
- Natalia Sudol
- Numero di telefono: +48 669 439 740
- Email: nat.sudol13@gmail.com
-
Warsaw, Polonia, 02-957
- Non ancora reclutamento
- Department of Pharmacology and Physiology of CNS
-
Investigatore principale:
- Justyna Holka-Pokorska
-
Warsaw, Polonia, 02-172
- Reclutamento
- MTZ Clinical Research Powered by Pratia
-
Investigatore principale:
- Monika Gawlowicz
-
-
-
-
-
Cambridge, Regno Unito, CB1 2EU
- Reclutamento
- Cambridge University Hospital NHS
-
Investigatore principale:
- Liliana Galindo
-
Contatto:
- Tracy Assari
- Numero di telefono: +44 1223 219751
- Email: t.assari@nhs.net
-
Contatto:
- Emma Tudor
- Numero di telefono: +44 1223 219751
- Email: Emma.tudor@cpft.nhs
-
Doncaster, Regno Unito, DN4 8QN
- Reclutamento
- Clerkenwell Health - Doncaster
-
Investigatore principale:
- Paul Morrison
-
Contatto:
- Celia Creaghan
- Numero di telefono: +44 7849 640886
- Email: ccreaghan@clerkenwellhealth.com
-
Edinburgh, Regno Unito, EH16 4TJ
- Non ancora reclutamento
- NHS Research Scotland
-
Investigatore principale:
- Donald MacIntyre
-
Contatto:
- Carrie Wardhaugh
- Numero di telefono: +44 1315375867
- Email: carrie.wardhaugh@ed.ac.uk
-
Glasgow, Regno Unito, G51 4TF
- Non ancora reclutamento
- Queen Elizabeth University Hospital
-
Investigatore principale:
- Maytal Wolfe
-
Contatto:
- Rebecca Baird
- Email: ggc.mentalhealthresearch@nhs.scot
-
Liverpool, Regno Unito, L7 8XP
- Non ancora reclutamento
- Royal Liverpool Hospital
-
Contatto:
- Rachel Crick
- Numero di telefono: +44730 861 3597
- Email: Rachel.Crick@merseycare.nhs.uk
-
Investigatore principale:
- Fabian Devlin
-
London, Regno Unito, EC2Y 8EA
- Reclutamento
- St Pancras Clinical Research
-
Investigatore principale:
- Martin Johnson
-
Contatto:
- Participant Engagement Team
- Numero di telefono: +44 20 38651142
- Email: studyinformation@stpancrasclinical.com
-
London, Regno Unito, W1U 6RP
- Reclutamento
- Clerkenwell Health - Baker Street
-
Investigatore principale:
- Alishah Suleman
-
Contatto:
- Takunda Gwenhure
- Numero di telefono: +44 2038974867
- Email: tgwenhure@clerkenwellhealth.com
-
Contatto:
- Victor Jardim
- Numero di telefono: +44 2038974867
- Email: vjardim@clerkenwellhealth.com
-
London, Regno Unito, W1G9 RU
- Reclutamento
- Re:Cognition Health
-
Investigatore principale:
- Dimitrios Paschos
-
Contatto:
- Numero di telefono: +44-0800-802-1030
-
London, Regno Unito, SE5 9RS
- Reclutamento
- King's College London
-
Contatto:
- Catheine Bird
- Email: catherine.bird@kcl.ac.uk
-
Contatto:
- Paige Seath
- Email: paige.seath@kcl.ac.uk
-
Investigatore principale:
- James Rucker
-
London, Regno Unito, W1G 8DR
- Ritirato
- Clerkenwell Health - Welbeck Street
-
Newcastle upon Tyne, Regno Unito, NE4 5PL
- Reclutamento
- Edwardson Building - Campus for Ageing and Vitality
-
Contatto:
- Victoria Wilson
- Numero di telefono: +44 191 246 8647
- Email: victoria.wilson3@cntw.nhs.uk
-
Contatto:
- Rebecca Woodhouse
- Email: Rebecca.Woodhouse@cntw.nhs.uk
-
Investigatore principale:
- Mourad Wahba
-
Reading, Regno Unito, RG7 8PA
- Reclutamento
- Ascend Clinical Research
-
Investigatore principale:
- Pamela Walters
-
Contatto:
- Alexandra Diaz
- Numero di telefono: +44 118 3045905
- Email: adiaz@ascendclinical-research.com
-
Sheffield, Regno Unito, S4 7QQ
- Reclutamento
- Sheffield Health and Social Care NHS Foundation Trust
-
Investigatore principale:
- William Gann
-
Contatto:
- Mishell Cunningham
- Numero di telefono: +44 114 271 6731
- Email: mishell.cunningham@sheffieldpartnership.nhs.uk
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35209
- Reclutamento
- UAB Psychiatry and Behavioral Neurology
-
Contatto:
- Seher Premani
- Numero di telefono: 205-996-1198
- Email: spremani@uab.edu
-
Investigatore principale:
- Peter Hendricks
-
Contatto:
- Maggie Gossage
- Email: mgossage@uabmc.edu
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85234
- Reclutamento
- Lighthouse Psychiatry
-
Contatto:
- Chung Trinh
- Numero di telefono: 435-268-5800
- Email: ctrinh@neosciclinicalresearch.com
-
Investigatore principale:
- Frank Genova
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72204
- Ritirato
- Pillar Clinical Research - Little Rock
-
-
California
-
Glendale, California, Stati Uniti, 91206
- Reclutamento
- Behavioral Research Specialists, LLC
-
Investigatore principale:
- Jesse Carr
-
Contatto:
- Laisha Uribe
- Numero di telefono: 888-255-5798
- Email: laisha@brstrials.com
-
Imperial, California, Stati Uniti, 92251
- Ritirato
- Sun Valley Research Center
-
Los Angeles, California, Stati Uniti, 90025
- Reclutamento
- CalNeuro Research Group
-
Investigatore principale:
- Alexander Bystritsky
-
Contatto:
- Numero di telefono: 310-208-7144
- Email: info@calneuroresearch.com
-
Los Angeles, California, Stati Uniti, 90025
- Reclutamento
- Lipov Medical Group
-
Contatto:
- Brittany Juhlmann
- Numero di telefono: 262-352-8835
- Email: brittany.juhlmann@stellacenter.com
-
Investigatore principale:
- Jacob Moussai
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- NRC Research Institute
-
Contatto:
- Christian Ortiz
- Numero di telefono: 714-289-1100
- Email: cortiz@nrcresearch.com
-
Investigatore principale:
- Daniel Chueh
-
Orange, California, Stati Uniti, 92866
- Reclutamento
- ATP Clinical Research
-
Investigatore principale:
- Gustavo Alva
-
Contatto:
- Sarah Perkins
- Numero di telefono: 949-354-5353
- Email: sarahp@pnsoc.com
-
San Juan Capistrano, California, Stati Uniti, 92675
- Reclutamento
- Inland Psychiatric Medical Group Inc (IPMG Research)
-
Investigatore principale:
- Neelima Kunam
-
Contatto:
- Numero di telefono: 909-955-5865
- Email: research@inlandpsych.com
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- Psychedelic Science Institute
-
Investigatore principale:
- Keith Heinzerling
-
Contatto:
- Numero di telefono: 213-973-7512
- Email: trialadmin@psychedelicsci.com
-
Stanford, California, Stati Uniti, 94305
- Ritirato
- Stanford University
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06511
- Reclutamento
- Yale School of Medicine - Yale Program for Psychedelic Science
-
Investigatore principale:
- Ben Kelmendi
-
Contatto:
- Daidre Chamberlain
- Numero di telefono: 203-693-1591
- Email: enact@yale.edu
-
Contatto:
- Terrence Ching
- Numero di telefono: 502-612-1127
- Email: terence.ching@yale.edu
-
-
Florida
-
Jacksonville, Florida, Stati Uniti, 32256
- Reclutamento
- CNS Healthcare
-
Contatto:
- Numero di telefono: 904-281-5757
-
Investigatore principale:
- John Mark Joyce
-
Maitland, Florida, Stati Uniti, 32751
- Reclutamento
- Accel Research Sites - Maitland
-
Contatto:
- Numero di telefono: 407-644-1165
-
Investigatore principale:
- Andrea Marrafino
-
Naples, Florida, Stati Uniti, 34105
- Reclutamento
- Aqualane Clinical Research
-
Investigatore principale:
- Matthew Baker
-
Contatto:
- Rachel Novella
- Numero di telefono: 239-529-6780
- Email: Rachel@Aqualaneresearch.com
-
Tampa, Florida, Stati Uniti, 33634
- Reclutamento
- K2 Medical Research Tampa
-
Investigatore principale:
- Kelley Wilson
-
Contatto:
- Jessica Myers
- Numero di telefono: 352-500-5252
- Email: Jessica.Myers@k2med.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Ritirato
- Emory University Dept of Psychiatry and Behavioral Studies
-
Marietta, Georgia, Stati Uniti, 30060
- Reclutamento
- Psych Atlanta
-
Investigatore principale:
- Michael Banov
-
Contatto:
- Numero di telefono: 770-422-2846
- Email: research@hightophealth.com
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- Reclutamento
- Rush University
-
Investigatore principale:
- Joshua Eloge
-
Contatto:
- Stephanie Gutierrez
- Numero di telefono: 312-942-8995
- Email: stephanie_z_gutierrez@rush.edu
-
-
Louisiana
-
Marrero, Louisiana, Stati Uniti, 70006
- Ritirato
- Tandem Clinical Research
-
New Orleans, Louisiana, Stati Uniti, 70115
- Reclutamento
- Atlas Psychiatry
-
Contatto:
- Milton Boresoff
- Numero di telefono: 504-899-1682
- Email: m.boresoff@atlaspsychiatry.com
-
Investigatore principale:
- Nicholas Pejic
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21224
- Ritirato
- Johns Hopkins Medicine
-
Rockville, Maryland, Stati Uniti, 20850
- Non ancora reclutamento
- Sunstone Medical, PC
-
Contatto:
- Manish Agrawal, MD
- Numero di telefono: 301-750-3401
- Email: Manish.agrawal@sunstonetherapies.com
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02116
- Reclutamento
- Adams Clinical Boston
-
Investigatore principale:
- Darin Dougherty
-
Contatto:
- Participant Navigators
- Numero di telefono: 617-404-4714
- Email: info@adamsclinical.com
-
Watertown, Massachusetts, Stati Uniti, 02472
- Reclutamento
- Adams Clinical Watertown
-
Investigatore principale:
- Stephanie Ellickson
-
Contatto:
- Participant Navigators
- Numero di telefono: 617-404-4714
- Email: info@adamsclinical.com
-
-
Minnesota
-
Eden Prairie, Minnesota, Stati Uniti, 55347
- Reclutamento
- Institute for Integrative Therapies
-
Investigatore principale:
- Manoj Doss
-
Contatto:
- Sena Ostwalt
- Numero di telefono: 6512808774
- Email: sena.ostwalt@iit-mn.com
-
Golden Valley, Minnesota, Stati Uniti, 55427
- Non ancora reclutamento
- The Remedy Mental Health
-
Contatto:
- Emmanuel Arhin
- Numero di telefono: (651) 382-9518
- Email: emmanuel.arhin@theremedymn.com
-
Investigatore principale:
- Wayne Bentham
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti, 89119
- Reclutamento
- Redbird Research, LLC
-
Investigatore principale:
- Jelena Kunovac
-
Contatto:
- Numero di telefono: 702-577-2000
- Email: info@redbird-research.com
-
-
New Jersey
-
Toms River, New Jersey, Stati Uniti, 08755
- Reclutamento
- Bio Behavioral Health
-
Contatto:
- Jessica Sutton
- Numero di telefono: 732-244-2299
- Email: jessica@bbhnj.com
-
Investigatore principale:
- Ashok Patel
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Non ancora reclutamento
- New York State Psychiatric Institute
-
Investigatore principale:
- Natalie Gukasyan
-
Contatto:
- Alexandra Mackay
- Numero di telefono: 212-342-1424
- Email: alexandra.mackay@nyspi.columbia.edu
-
New York, New York, Stati Uniti, 10029
- Reclutamento
- Adams Clinical Harlem
-
Contatto:
- Participant Navigators
- Numero di telefono: 917-454-3746
- Email: info@adamsclinical.com
-
Investigatore principale:
- Wesley Gregory
-
The Bronx, New York, Stati Uniti, 10461
- Reclutamento
- Adams Clinical Bronx
-
Investigatore principale:
- Shama Farooq
-
Contatto:
- Participant Navigators
- Numero di telefono: 917-454-3746
- Email: info@adamsclinical.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73112
- Ritirato
- SP Research PLLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Adams Clinical Philadelphia
-
Investigatore principale:
- Cassie Blanchard
-
Contatto:
- Participant Navigators
- Numero di telefono: 267-376-0266
- Email: info@adamsclinical.com
-
Philadelphia, Pennsylvania, Stati Uniti, 19462
- Reclutamento
- Flourish Research Philadelphia
-
Investigatore principale:
- Rachna Saralkar
-
Contatto:
- Numero di telefono: 215-614-5606
-
-
Texas
-
Austin, Texas, Stati Uniti, 78737
- Ritirato
- Austin Clinical Trial Partners
-
DeSoto, Texas, Stati Uniti, 75115
- Reclutamento
- Adams Clinical Dallas
-
Investigatore principale:
- Rajinder Shiwach
-
Contatto:
- Participant Navigators
- Numero di telefono: 469-379-2494
- Email: info@adamsclinical.com
-
Fort Worth, Texas, Stati Uniti, 76104
- Ritirato
- North Texas Clinical Trials
-
Houston, Texas, Stati Uniti, 77046
- Reclutamento
- Brain Health Consultants and TMS Center
-
Investigatore principale:
- Lauren Marangell
-
Contatto:
- Numero di telefono: 713-489-5000
- Email: info@brainhealthconsultants.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Flourish Research San Antonio
-
Investigatore principale:
- Parke Hedges
-
Contatto:
- Xavier Martinez
- Numero di telefono: 237 210-949-0122
- Email: xmartinez@flourishresearch.com
-
Contatto:
- Andrea Gomez
- Numero di telefono: 122 210-949-0122
- Email: agomez@flourishresearch.com
-
-
Washington
-
Everett, Washington, Stati Uniti, 98201
- Non ancora reclutamento
- Core Clinical Research
-
Contatto:
- Maria Golescu
- Numero di telefono: 425-443-9551
- Email: maria.golescu@ccrtrial.com
-
Investigatore principale:
- James Knutson
-
Seattle, Washington, Stati Uniti, 98104
- Reclutamento
- Seattle Neuropsychiatric Treatment Center
-
Investigatore principale:
- Rebecca Allen
-
Contatto:
- Numero di telefono: 5 206-467-6300
- Email: research@seattlentc.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Participants must meet all the following criteria to be included in the trial:
- Age18 to 85 years.
- Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
- Moderate to severe depression at Screening and Baseline, independently confirmed.
- Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
- Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening.
- Participant is able to refrain from nicotine use during the dosing session (up to 8 hours).
- Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
- Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
- Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy.
- Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Exclusion Criteria
Participants with any of the following characteristics/conditions will be excluded from trial participation:
- Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
- Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD.
- Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives).
- Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
- Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
- Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
- Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
- Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
- Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
- Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
- Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
- Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate.
- Participants have a presence or relevant history of organic brain disorders.
- Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration.
- Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing.
- Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
- Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
- History of serotonin syndrome.
- Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental Arm A CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 8 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Sperimentale: Experimental Arm B CYB003 in 2 of 2 Dosing Sessions
Experimental Arm B participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. |
CYB003 is a deuterated psilocin analog. Manualized psychological support performed by facilitator. |
|
Comparatore placebo: Placebo Comparator: Arm C Placebo in 2 of 2 Dosing Session
Participants will receive placebo in 2 of 2 medicine sessions, approximately three weeks apart. All Arm C participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial. |
Manualized psychological support performed by facilitator. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Montgomery-Asberg Depression Scale (MADRS)
Lasso di tempo: Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phased questions about symptoms to more detailed ones allowing a precise rating of severity. The total score ranges 0-60, higher scores denote greater severity. |
Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The Beck Depression Inventory - Second Edition (BDI-II)
Lasso di tempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity. Each question is scored on a scale value of 0 to 3, with higher total scores indicating more severe depressive symptoms. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II, so the total score possible is 63 and minimum if everything is zero would be 0. |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
|
The Clinical Global Impression Scale (CGI-S)
Lasso di tempo: Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement and efficacy index. Only the severity of illness ang global improvement measures will be utilized for this trial. Higher score means more severe symptomology, worse outcome. CGI-S scoring is as follows:
|
Screening Day-45, Baseline Day -1, Day 42, Day 84/End of Trial.
|
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7)
Lasso di tempo: Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
The Generalized Anxiety Disorder 7-Item Scale (GAD-7) is a 7-item self reported assessment that measures the severity of generalized anxiety disorder symptoms. Participants respond to each item using a 4-point scale from 0 to 3. Participants choose one of 4 severity scores associated with problems related to the common anxiety disorders to indicate the degree to which these problems caused functional and/or social difficulties. A total score is obtained by the sum of all total column values, higher scores indicate more functional/social impairment/difficulties. Score range is as follows: Scores represent: 0 - 4 = Minimal anxiety 5 - 9 = Mild anxiety 10 - 14 = Moderately anxiety 15 - 21 = Severe anxiety |
Baseline Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.
|
|
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Lasso di tempo: Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self reported measure used to evaluate intervention-related changes in quality of life, divided int the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial. Each item rated on a 5-point scale ranging from 1 (very poor) to 5 (very good), higher score indicates greater satisfaction. The scoring of the Q-LES-Q-SF involves summing only the first 14 items to yield a raw total score. The last two items are not included in the total score but are standalone items. The raw total score ranges from 14 to 70. So the minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 |
Day -1, Day 21, Day 42 and Day 84/End of Trial.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Felix Mazer, Cybin IRL Limited
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CYB003-003
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .